This article has been updated from a previous version to clarify the company's reimbursement goals for 2013.

SAN FRANCISCO (GenomeWeb News) – Sequenom Chairman and CEO Harry Hixson on Wednesday expressed confusion over Illumina's decision to acquire Verinata for a price that could climb to $450 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.